Read by QxMD icon Read

gleason grades

Anna Wilkins, Christine Stuttle, Shama Hassan, Claire Blanchard, Clare Cruickshank, Clare Griffin, Jake Probert, Catherine M Corbishley, Chris Parker, David Dearnaley, Emma Hall
Background: This article presents the methodology for tissue sample collection in Trans-CHHiP, the main translational study within the CHHiP (Conventional or Hypofractionated High dose intensity modulated radiotherapy in Prostate cancer, ISRCTN 97182923) trial. The CHHiP trial randomised 3216 men with localised prostate cancer to 3 different radiotherapy fractionation schedules. Trans-CHHiP aims to identify biomarkers of fraction sensitivity. Methods: We outline the process of tissue collection, including central review by a study-specific specialist uropathologist and comparison of the centrally-assigned Gleason grade group with that assigned by the recruiting-centre pathologist...
March 2018: Clinical and Translational Radiation Oncology
Martina Kluth, Sekander Scherzai, Franziska Büschek, Christoph Fraune, Katharina Möller, Doris Höflmayer, Sarah Minner, Cosima Göbel, Christina Möller-Koop, Andrea Hinsch, Emily Neubauer, Maria Christina Tsourlakis, Guido Sauter, Hans Heinzer, Markus Graefen, Waldemar Wilczak, Andreas M Luebke, Eike Burandt, Stefan Steurer, Thorsten Schlomm, Ronald Simon
Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12,000 cancer samples with full pathological and clinical follow up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7,375 analyzable cancers...
June 20, 2018: Genes, Chromosomes & Cancer
Nishi Karunasinghe, Stefan Ambs, Alice Wang, Wei Tang, Shuotun Zhu, Tiffany H Dorsey, Megan Goudie, Jonathan G Masters, Lynnette R Ferguson
INTRODUCTION: The prostate-specific antigen (PSA) based prostate cancer (PC) screening is currently being debated. The current assessment is to understand the variability of detecting high-risk PC in a NZ cohort in comparison to a US cohort with better PSA screening facilities. Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions with a potential to regulate subsequent PSA levels. Therefore, we wish to understand the influence of tobacco smoking and the AKR1C3 rs12529 gene polymorphism in this variability...
2018: PloS One
Waldemar Wilczak, Corinna Wittmer, Till Clauditz, Sarah Minner, Stefan Steurer, Franziska Büscheck, Till Krech, Maximilian Lennartz, Luisa Harms, Diane Leleu, Marc Ahrens, Sebastian Ingwerth, Christian T Günther, Christina Koop, Ronald Simon, Frank Jacobsen, Maria C Tsourlakis, Viktoria Chirico, Doris Höflmayer, Eik Vettorazzi, Alexander Haese, Thomas Steuber, Georg Salomon, Uwe Michl, Lars Budäus, Derya Tilki, Imke Thederan, Christoph Fraune, Cosima Göbel, Marie-Christine Henrich, Manuela Juhnke, Katharina Möller, Ahmed Abdullah Bawahab, Ria Uhlig, Meike Adam, Sören Weidemann, Burkhard Beyer, Hartwig Huland, Markus Graefen, Guido Sauter, Thorsten Schlomm
BACKGROUND: Nodal metastasis (N1) is a strong prognostic parameter in prostate cancer; however, lymph node evaluation is always incomplete. OBJECTIVE: To study the prognostic value of lymphatic invasion (L1) and whether it might complement or even replace lymph node analysis in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of pathological and clinical data from 14 528 consecutive patients. INTERVENTION: Radical prostatectomy...
June 13, 2018: European Urology
Nicholas P Meermeier, Kevin R Turner, Bryan R Foster, Csanád Várallyay, Jen-Jane Liu, Fergus V Coakley
PURPOSE: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. MATERIALS AND METHODS: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy...
June 9, 2018: Clinical Imaging
Wei Gang Wang, Di Yan, Hong Ye, Gary Gustafson, Michael Ghilezan, Alvaro Martinez, Daniel Krauss
Purpose: The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer. Methods and materials: Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved, and had prostate-specific antigen levels ≤10 ng/mL...
April 2018: Advances in Radiation Oncology
Shengmeng Peng, Tao Du, Wanhua Wu, Xianju Chen, Yiming Lai, Dingjun Zhu, Qiong Wang, Xiaoming Ma, Chunhao Lin, Zean Li, Zhenghui Guo, Hai Huang
PURPOSE: The aim of this study was to investigate the associations of serine proteinase inhibitor family G1 (SERPING1) down-regulation with poor prognosis in patients with prostate cancer (PCa). Furthermore, we aim to find more novel and effective PCa molecular markers to provide an early screening of PCa, distinguish patients with aggressive PCa, predict the prognosis, or reduce the economic burden of PCa. METHODS: SERPING1 protein expression in both human PCa and normal prostate tissues was detected by immunohistochemical staining, which intensity was analyzed in association with clinical pathological parameters such Gleason score, pathological grade, clinical stage, tumor stage, lymph node metastasis, and distant metastasis...
June 11, 2018: Urologic Oncology
Aline C Tregnago, Jonathan I Epstein
Skene's (periurethral) gland adenocarcinoma is very rare, with only 7 cases reported in the literature. This is the first series of cases on this entity. We describe the histologic, immunohistochemical, and clinical findings of 4 patients with Skene's gland adenocarcinoma retrieved from the Johns Hopkins Urologic Pathology Consult Service from 1984 to 2017. The average age at diagnosis of the 4 women was 74.5 years (range, 61 to 87 y). Tumors were treated by limited resections with negative margins. Tumor size ranged from 1...
June 12, 2018: American Journal of Surgical Pathology
Cosimo De Nunzio, Riccardo Lombardo, Giorgia Tema, Hassan Alkhatatbeh, Giorgio Gandaglia, Alberto Briganti, Andrea Tubaro
OBJECTIVES: The aim of our study was to analyze the performance of 5 different risk calculators for prostate cancer diagnosis: Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC), European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSP-RC), Karakiewicz nomogram, Chun nomogram, and Kawakami Nomogram. METHODS: From 2008 onwards, we consecutively enrolled, at a single institution in Italy, men undergoing 12-core transrectal ultrasound-guided prostate needle biopsy...
June 4, 2018: Urologic Oncology
Samson W Fine, Hikmat A Al-Ahmadie, Ying-Bei Chen, Anuradha Gopalan, Satish K Tickoo, Victor E Reuter
From the advent of the Gleason grading system for prostate cancer, cancer displaying intraluminal necrotic cells and/or karyorrhexis within cribriform/solid architecture, a phenomenon termed "comedonecrosis," has been assigned pattern 5. Intraductal carcinoma (IDC-P) shows morphologic overlap with high-grade cribriform/solid adenocarcinoma architecturally and cytologically and may also show central necrosis, yet due to the presence of basal cells at the duct periphery is not currently assigned a grade in clinical practice...
June 6, 2018: American Journal of Surgical Pathology
Andreas Maxeiner, Thomas Fischer, Julia Schwabe, Alexander Daniel Jacques Baur, Carsten Stephan, Robert Peters, Torsten Slowinski, Maximilian von Laffert, Stephan Rodrigo Marticorena Garcia, Bernd Hamm, Ernst-Michael Jung
PURPOSE:  The aim of this study was to investigate contrast-enhanced ultrasound (CEUS) parameters acquired by software during magnetic resonance imaging (MRI) US fusion-guided biopsy for prostate cancer (PCa) detection and discrimination. MATERIALS AND METHODS:  From 2012 to 2015, 158 out of 165 men with suspicion for PCa and with at least 1 negative biopsy of the prostate were included and underwent a multi-parametric 3 Tesla MRI and an MRI/US fusion-guided biopsy, consecutively...
June 6, 2018: Ultraschall in der Medizin
Inderbir S Gill, Abdel-Rahmene Azzouzi, Mark Emberton, Jonathan A Coleman, Emmanuel Coeytaux, Avigdor Scherz, Peter T Scardino
INTRODUCTION: The prospective trial PCM301 randomized 413 men with low-risk prostate cancer to partial gland ablation with vascular-targeted photodynamic therapy (n=207) or active surveillance (n=206). Two-year outcomes were reported previously. Here we report four-year rates of intervention with radical therapy and further assess efficacy with biopsy results. MATERIALS & METHODS: Prostate biopsies were mandated at 12 and 24 months. Thereafter, patients were monitored for radical therapy, with periodic biopsies performed according to standard-of-care in each institution...
June 1, 2018: Journal of Urology
Chun-Peng Liao, Tzu-Ping Lin, Pei-Chuan Li, Lauren A Geary, Kevin Chen, Vijaya Pooja Vaikari, Jason Boyang Wu, Chi-Hung Lin, Mitchell E Gross, Jean C Shih
Monoamine oxidase A (MAOA) is a mitochondrial enzyme, which degrades monoamine neurotransmitters and dietary amines and produces H2 O2 . Recent studies have shown increased MAOA expression in prostate cancer (PCa), glioma, and classical Hodgkin lymphoma. However, the biological function of MAOA in cancer development remains unknown. In this study, we investigated the role of MAOA in the development of prostate adenocarcinoma by creating a prostate-specific Pten/MAOA knockout (KO) mouse model, in which MAOA-floxP mouse was crossed with the conditional Pten KO PCa mouse that develops invasive PCa...
May 29, 2018: Oncogene
Marine Daures, Mouhamed Idrissou, Gaëlle Judes, Khaldoun Rifaï, Frédérique Penault-Llorca, Yves-Jean Bignon, Laurent Guy, Dominique Bernard-Gallon
Histone methylation is essential for gene expression control. Trimethylated lysine 27 of histone 3 (H3K27me3) is controlled by the balance between the activities of JMJD3 demethylase and EZH2 methyltransferase. This epigenetic mark has been shown to be deregulated in prostate cancer, and evidence shows H3K27me3 enrichment on gene promoters in prostate cancer. To study the impact of this enrichment, a transcriptomic analysis with TaqMan Low Density Array (TLDA) of several genes was studied on prostate biopsies divided into three clinical grades: normal ( n = 23) and two tumor groups that differed in their aggressiveness (Gleason score ≤ 7 ( n = 20) and >7 ( n = 19))...
May 4, 2018: Oncotarget
Jin A Baek, Phil Hyun Song, YoungHwii Ko, Mi Jin Gu
Prostate cancer is the most common malignancy in men, and biologically shows highly heterogeneous clinical outcomes, despite early detection. Therefore, the identification of novel molecular markers that are associated with biological aggressiveness is very important for prostatic cancer clinical outcome predictions and treatment choices. Here, we investigate quiescin sulfhydryl oxidase 1 (QSOX1) expression and evaluate its clinicopathological significance and prognostic impact in prostate cancers, with immunohistochemistry on tissue microarrays...
May 22, 2018: Pathology, Research and Practice
Saranya Prathibha, Kashika G Goyal, Debra L Zynger
Extended prostate needle core biopsies are standard of care for the diagnosis of prostatic carcinoma. Subsequent biopsies may be performed for a variety of indications. Knowledge of biopsy characteristics indicating risk for progression may have utility to guide therapeutic management. Prostate needle core biopsies performed between 2008-2014 were reviewed. Patients with at least 1 subsequent biopsy were identified. Cases were categorized by worst initial diagnosis. Gleason ≤6 carcinoma was further classified as significant or insignificant with insignificant defined as: ≤2 cores with carcinoma, sites with ≤50% carcinoma, and unilateral carcinoma...
May 24, 2018: Human Pathology
Emily Neubauer, Morwari Latif, Jenny Krause, Asmus Heumann, Moritz Armbrust, Clara Luehr, Christoph Fraune, Claudia Hube-Magg, Martina Kluth, Christina Möller-Koop, Guido Sauter, Ronald Simon, Burkhard Beyer, Raisa S Pompe, Imke Thederan, Thorsten Schlomm, Franziska Büscheck
HSD3B2 plays a crucial role in steroid hormone biosynthesis and is thus of particular interest in hormone dependent tumors such as prostate cancer. To clarify the clinical relevance of HSD3B2 expression in prostate cancer, we analyzed HSD3B2 protein expression by immunohistochemistry on our preexisting tissue microarray with 12.247 annotated cancers. Compared with normal tissue cytoplasmic HSD3B2 staining was stronger in prostate cancers. In 9371 interpretable cancers, HSD3B2 expression was found in 95.5% of cancers and was considered weak in 29...
May 24, 2018: Experimental and Molecular Pathology
Melanie A Evans, Jeremy L Millar, Arul Earnest, Mark Frydenberg, Ian D Davis, Declan G Murphy, Paul Aidan Kearns, Sue M Evans
OBJECTIVE: To characterise the practice of active surveillance (AS) for men with low risk prostate cancer by examining the characteristics of those who commence AS, the rate of adherence to accepted AS follow-up protocols over 2 years, and factors associated with good adherence. Design, setting: Retrospective cohort study; analysis of data collected from 38 sites participating in the Prostate Cancer Outcomes Registry-Victoria. PARTICIPANTS: Men diagnosed with prostate cancer between August 2008 and December 2014 aged 75 years or less at diagnosis, managed by AS for at least 2 years, and with an ISUP grade group of 3 or less (Gleason score no worse than 4 + 3 = 7)...
June 4, 2018: Medical Journal of Australia
Simone Albisinni, Christian Melot, Fouad Aoun, Ksenija Limani, Alexandre Peltier, Pascal Rischmann, Roland van Velthoven
BACKGROUND: Focal therapy for prostate cancer (PCa) remains experimental. Aim of the current study is to review available evidence and perform a pooled analysis exploring oncologic and functional results of High Intensity Focal Ultrasound (HIFU) focal therapy for the treatment of unilateral PCa. METHODS: The National Library of Medicine Database was searched for relevant articles. A wide search was performed including the combination of following words: "HIFU", "prostate", "cancer", "focal"...
May 23, 2018: Journal of Endourology
Rodrigo Hepp, Thilo Eggert, Georg Schabl, Lars Herberholz, Tim Petry, Razvan Galalae
Purpose: The aim of this study is to determine if a repeated hydrogel injection in a previously irradiated patient prior to salvage high-dose-rate brachytherapy (HDR-BT) is feasible. Material and methods: A 61-year-old man with an organ confined (cT1c cN0 cM0, Gleason score 3 + 3 = 6, initial prostate-specific antigen [PSA] 7.9 ng/ml) prostate cancer was previously treated with HDR-BT (3 fractions of 11.5 Gy every 2nd week) after hydrogel injection to reduce the rectal dose...
April 2018: Journal of Contemporary Brachytherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"